Dosing Optimisation with BeneFIX

Achieving Medicines Optimisation with BeneFIX

What is medicines optimisation and what are the benefits?

Medicines optimisation is a patient focused approach which aims to improve the outcome for patient treatment, by making sure that medicines are being used safely and in the most effective way possible. 1,2 It also allows the NHS to make sure that medicines being used are both clinically and cost effective.1

BeneFIX is competitively priced and delivers value both financially and for patients, allowing for optimisation of NHS resources.

The quality of life for patients with haemophilia can be greatly improved through reduced bleeds and by aiming to keep baseline factor level above 5% which reduces the chance of spontaneous bleeding.3

How can BeneFIX allow for improved medicines optimisation?

  • Cost effective treatment for patients
  • Range of Vial sizes – which allows for individualised dosing4
  • Storage flexibility – can be stored at room temperature (<30C)4
  • Predictable pharmacokinetic profile

How medicines optimisation with BeneFIX can improve a patient's lifestyle5,6

  • Aims to increase coverage for day to day activities
  • Aims to prevent spontaneous breakthrough bleeding
  • Aims to prevent subclinical bleeding and ensuing joint damage


  1. Medicines Optimisation. Accessed: March 2020.
  2. Medicines Optimisation: the safe and effective use of medicines to enable the best possible outcomes. Accessed: March 2020
  3. Shapiro A et al. Association of Bleeding Tendency With Time Under Target FIX Activity Levels In Severe Haemophilia B Patients Treated With Recombinant Factor IX Fc Fusion Protein. Blood. 2013:122(21): 2349.
  4. Benefix® (nonacog alfa) Summary of Characteristics. December 2018.
  5. Shapiro AD et al. Use of pharmacokinetics in the coagulation factor treatment of patients with haemophilia. Haemophilia 2005;11:571–582
  6. Jiménez-Yuste, V. et al. Achieving and maintaining an optimal trough level for prophylaxis in haemophilia: the past, the present and the future. Blood Transfusion. 2014:12(3): 314-319


PP-BEN-GBR-0343. March 2020